Byfavo(remimazolam)
Byfavo (remimazolam) is a small molecule pharmaceutical. Remimazolam was first approved as Byfavo on 2020-10-06. It has been approved in Europe to treat conscious sedation.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| anesthesia and analgesia | D000760 |
Trade Name
FDA
EMA
Byfavo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Remimazolam besylate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BYFAVO | Acacia Pharma | N-212295 RX | 2020-10-06 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| byfavo | New Drug Application | 2025-02-20 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
REMIMAZOLAM BESYLATE, BYFAVO, ACACIA | |||
| 2025-10-06 | NCE | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Remimazolam Besylate, Byfavo, Acacia | |||
| 9561236 | 2033-04-30 | U-2968 | |
| 9737547 | 2031-11-07 | U-2968 | |
| 9827251 | 2031-11-07 | U-2968 | |
| 10052334 | 2031-11-07 | U-2968 | |
| 10195210 | 2031-11-07 | U-2968 | |
| 10342800 | 2031-11-07 | U-2968 | |
| 10722522 | 2031-11-07 | U-2968 | |
| 9777007 | 2027-07-10 | DP | |
| 9914738 | 2027-07-10 | DP | |
| 10472365 | 2027-07-10 | U-2968 | |
| 10961250 | 2027-07-10 | DP | U-2968 |
HCPCS
No data
Clinical
Clinical Trials
246 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anesthesia | D000758 | — | — | 1 | — | 1 | — | — | 2 |
| Colonoscopy | D003113 | — | — | — | — | 2 | — | — | 2 |
| Intravenous anesthesia | D000771 | — | — | — | — | 1 | — | — | 1 |
| Bronchoscopy | D001999 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| General anesthesia | D000768 | — | — | — | 1 | — | — | — | 1 |
| Endoscopy | D004724 | — | — | — | 1 | — | — | — | 1 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | — | — | — | 1 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | 1 | — | — | — | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | — | — | — | 1 |
| Respiratory insufficiency | D012131 | — | J96.9 | — | 1 | — | — | — | 1 |
| Shock | D012769 | — | R57.1 | — | 1 | — | — | — | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Remimazolam |
| INN | remimazolam |
| Description | Remimazolam, sold under the brand name Byfavo, is a medication for the induction and maintenance of procedural sedation in adults for invasive diagnostic or surgical procedures lasting 30 minutes or less. It is a benzodiazepine drug, developed by PAION AG in collaboration with several regional licensees as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in the induction of anesthesia and conscious sedation for minor invasive procedures. Remimazolam was found to have both a more rapid onset and a shorter duration than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21 |
Identifiers
| PDB | — |
| CAS-ID | 308242-62-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297526 |
| ChEBI ID | — |
| PubChem CID | 9867812 |
| DrugBank | DB12404 |
| UNII ID | 7V4A8U16MB (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,316 documents
View more details
Safety
Black-box Warning
Black-box warning for: Byfavo
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
138 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use